Sven Wehrwein, an insider at AtriCure Inc (ATRC), recently acquired 39,341 shares of the company at a price of $19.95 per share, totaling approximately $785,000. Following this transaction, Wehrwein now holds a total of 39,341 shares of AtriCure.
This insider purchase underscores a potential confidence in AtriCure's future prospects. AtriCure, based in Mason, Ohio, specializes in the development, manufacture, and sale of surgical ablation systems for cardiac tissue and left atrial appendage exclusion. The company has a market capitalization of $1.6 billion and employs around 1,300 full-time staff.
As of November 18, 2025, AtriCure reported an earnings per share (EPS) of -0.62. Upcoming earnings reports are expected on April 27, 2026, and July 27, 2026, with estimated EPS of -0.11 and -0.04, respectively, alongside revenue estimates of $141.4 million and $155.3 million.
While insider transactions can be seen as a positive signal, they should not be the sole factor in investment decisions. Investors are encouraged to analyze broader patterns of insider activity and consider other fundamental and technical factors when evaluating company performance.